No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs

被引:9
|
作者
Rasmussen, M [1 ]
Poulsen, PH
Treiber, A
Delahaye, S
Tankisi, A
Cold, GE
Therkelsen, K
Gjedde, A
Astrup, J
机构
[1] Aarhus Univ Hosp, Dept Neuroanaesthesia, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Neurosurg, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Positron Emiss Tomog Ctr, DK-8000 Aarhus C, Denmark
[4] Aalborg Gen Hosp, Dept Clin Chem, Aalborg, Denmark
[5] Actel Pharmaceut Ltd, Allschwil, Switzerland
关键词
bosentan; cerebral blood flow; cerebral metabolic rate of oxygen; endothelin; indomethacin; positron emission tomography;
D O I
10.1034/j.1399-6576.2003.00019.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: The mechanism behind indomethacin-induced cerebral vasoconstriction is incompletely understood. We tested the hypothesis that the mixed endothelin-1 receptor antagonist bosentan would modify or prevent indomethacin-induced reduction of CBF in the anaesthetized pig. Furthermore, we investigated the effect of bosentan on resting CBF and CMRO2. Methods: Twelve pigs were randomized in two groups of six, and received either bosentan and indomethacin (group 1), or placebo and indomethacin (group 2). Anaesthesia was induced with ketamine and midazolam and maintained with fentanyl, nitrous oxide and pancuronium. Baseline measurements of CBF and CMRO2 were performed before intravenous bolus injection of bosentan (10 mg/kg) or placebo (0.9% NaCl). The second CBF and CMRO2 measurement was performed 30 min after administration of bosentan/placebo. A 40-min infusion of indomethacin (0.05 mg/kg/min) was administered and the third CBF and CMRO2 measurement was performed 80 min after administration of bosentan/placebo. Independently, pharmacokinetic data of bosentan were generated in four pigs. Results: In group 1, baseline CBF was 55 +/- 7 ml/100 cm(3) /min. Administration of bosentan i.v. did not change CBF significantly. Indomethacin decreased CBF to 41 +/- 5 ml/100 cm(3)/min (P < 0.002). In group 2, baseline CBF was 54 +/- 10 ml/100 cm(3) /min. Placebo did not change CBF while indomethacin decreased CBF significantly to 41 +/- 5 ml/100 cm(3)/min (P < 0.002). No significant changes in CMRO2 were observed. In group 2, a significant increase in MABP was observed after administration of indomethacin. No change in MABP was observed in the bosentan-treated animals. Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 mug/ml, respectively. The corresponding values for the pharmacologically active metabolite Ro 48-5033 were 1.2 and 0.4 mug/ml. Conclusion: These findings indicate that endothelin receptor stimulation is not involved in indomethacin-induced cerebral vasoconstriction or maintenance of cerebrovascular tone in the anaesthetized pig. However, our results suggest that the increase in MABP is mediated through endothelin receptors.
引用
收藏
页码:200 / 207
页数:8
相关论文
共 50 条
  • [41] Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow
    Santos, CL
    Souza, MHLP
    Gomes, AS
    Lemos, HP
    Santos, AA
    Cunha, FQ
    Wallace, JL
    BRITISH JOURNAL OF PHARMACOLOGY, 2005, 146 (04) : 481 - 486
  • [42] SUPERIOR MESENTERIC-ARTERY BLOOD-FLOW AND INDOMETHACIN-INDUCED INTESTINAL INJURY AND INFLAMMATION
    BATTARBEE, HD
    GRISHAM, MB
    JOHNSON, GG
    ZAVECZ, JH
    EDWARDS, SR
    GASTROENTEROLOGY, 1995, 108 (04) : A272 - A272
  • [43] ENDOTHELIN-1 (ET-1) INDUCED RENAL DYSFUNCTION IS ABOLISHED BY RECEPTOR ANTAGONIST BUT NOT BY INDOMETHACIN
    BHAT, R
    JOHN, E
    CHARI, G
    FORNELL, L
    SHANKARARAO, R
    GULATI, A
    VIDYASAGAR, D
    FASEB JOURNAL, 1994, 8 (04): : A585 - A585
  • [44] Acute effect of a selective endothelin-A receptor antagonist, S-0139, against cyclosporine-induced reduction in renal cortical blood flow
    Akira Ishikawa
    Kazuo Suzuki
    Kimio Fujita
    Clinical and Experimental Nephrology, 1997, 1 (4) : 297 - 300
  • [45] EFFECT OF INDOMETHACIN ON BASAL AND CARBON-DIOXIDE STIMULATED CEREBRAL BLOOD-FLOW IN MAN
    WENNMALM, A
    ERIKSSON, S
    WAHREN, J
    CLINICAL PHYSIOLOGY, 1981, 1 (02): : 227 - 234
  • [46] Endothelin contributes to blood pressure elevations in patients with mild-moderate essential hypertension: Evidence from treatment with a mixed endothelin receptor antagonist, bosentan
    Krum, H
    Budde, M
    Charlon, V
    CIRCULATION, 1997, 96 (08) : 3340 - 3340
  • [47] Effect of the endothelin receptor antagonist bosentan on chronic hypoxia-induced morphological and physiological changes in rat carotid body
    Chen, Jia
    He, Liang
    Liu, Xuemei
    Dinger, Bruce
    Stensaas, Larry
    Fidone, Salvatore
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2007, 292 (05) : L1257 - L1262
  • [48] The endothelin-I receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans
    Böhm, F
    Settergren, M
    Gonon, AT
    Pernow, J
    CLINICAL SCIENCE, 2005, 108 (04) : 357 - 363
  • [49] ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN AMELIORATES COLLAGEN-INDUCED ARTHRITIS IN MICE AND MODULATES GENE EXPRESSION IN LYMPH NODES
    Cunha, T. M.
    Donate, P. B.
    Verri, W. A., Jr.
    Junta, C. M.
    Vieira, S. M.
    Louzada, P., Jr.
    Donadi, E. A.
    Passos, G. A.
    Cunha, F. Q.
    INFLAMMATION RESEARCH, 2011, 60 : 281 - 282
  • [50] THE ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN PREVENTS SHORT-TERM HYPOXIA-INDUCED PULMONARY-HYPERTENSION IN THE RATS
    CHEN, SJ
    CHEN, YF
    MENG, QC
    OPARIL, S
    CIRCULATION, 1994, 90 (04) : 151 - 151